Behavioral activation for depressed patients in Iran: Effectiveness, predictors and mediators in the context of a randomized trial

Citation for published version (APA):

Document status and date:
Published: 01/01/2015

Document Version:
Publisher's PDF, also known as Version of record

Please check the document version of this publication:
• A submitted manuscript is the version of the article upon submission and before peer-review. There can be important differences between the submitted version and the official published version of record.
  People interested in the research are advised to contact the author for the final version of the publication, or visit the DOI to the publisher's website.
• The final author version and the galley proof are versions of the publication after peer review.
• The final published version features the final layout of the paper including the volume, issue and page numbers.

Link to publication

General rights
Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.
• Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
  • You may not further distribute the material or use it for any profit-making activity or commercial gain
  • You may freely distribute the URL identifying the publication in the public portal.

If the publication is distributed under the terms of Article 25fa of the Dutch Copyright Act, indicated by the “Taverne” license above, please follow below link for the End User Agreement:
www.umlib.nl/taverne-license

Take down policy
If you believe that this document breaches copyright please contact us at:
repository@maastrichtuniversity.nl
providing details and we will investigate your claim.

Download date: 15 Jun. 2020
Valorisation addendum
Impact of depression on quality of life, health, and society

Depression is considered by the World Health Organization (WHO) to be the second greatest cause of disability in the world (Murray and Lopez, 1997; Mathers CD, Stein C, Ma Fat D, et al, 2002; WHO, 2004). Depression is described as a chronic disorder and follows a pattern of relapse and remission that is related to illness burdens that falls into two broad categories (Klerman and Weissman, 1992). The first is the burden of illness experienced by the depressed patients, including discomfort, pain or distress, or problems in conducting the activities of daily life. The second is the extensive economic burden that consists of the costs of providing social and health care, loss of productivity and time off work, the burden on caregivers, and loss of wages. Moreover, depression has been regarded as a condition that is “chronic and recurrent in nature, impairs family life, reduces social adjustment, and is a burden on the community” (Klerman and Weissman, 1992).

Depression is associated with an extensive domain of mental health problems and interferes with the experience of positive well-being. Various components of quality of life are influenced by depression. It is quite clear that depression is related to impairment and disabilities in role functioning. Depression can impair social functioning and thereby have a negative influence on patients’ life. Thus, by reducing psychological well-being, impairing role functioning and depriving patients of social support, depression may lead to a reduced overall quality of life.

In addition to the subjective suffering experienced by those who are depressed, the impact on social and occupational functioning, physical health and mortality is quite evident. Depressive disorders bring about a greater decrease in health state than major chronic physical illnesses like angina, arthritis, asthma, and diabetes (Moussavi et al, 2007).

Therefore, effective treatment (s) for depression that can be conducted by many mental health professionals around the globe that is cost-effective and has enduring effects for patients is necessary. Moreover, easy implementation and dissemination of the treatment for depression is another issue to be considered. Most patients with MDD in Iran will have access to antidepressants (ADM) when they see a general practitioner or a psychiatrist for their first visit. Thus, ADM are commonly prescribed for depressed patients. The results of our study indicated that BA treatment is at least as effective as ADM and acceptable for depressed patients, even for those patients that are severely depressed. However, the most available treatment for depression is still ADM, although psychological treatments often have higher acceptability and better long-term effects than ADM.